Beam Therapeutics BEAM Employee Related Expenses — Research And Development Expense
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Beam Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Beam Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Beam Therapeutics's employee related expenses — research and development expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Beam Therapeutics's employee related expenses — research and development expense?
- Beam Therapeutics (BEAM) reported employee related expenses — research and development expense of $32.87M in Q1 2026.
- How has Beam Therapeutics's employee related expenses — research and development expense changed year-over-year?
- Beam Therapeutics's employee related expenses — research and development expense increased by 12.4% year-over-year, from $29.24M to $32.87M.
- What is the long-term trend for Beam Therapeutics's employee related expenses — research and development expense?
- Over 3 years (2022 to 2025), Beam Therapeutics's employee related expenses — research and development expense has grown at a 9.4% compound annual growth rate (CAGR), from $89.55M to $117.37M.
- What does employee related expenses — research and development expense mean?
- This metric represents the portion of total research and development costs specifically attributable to personnel-related expenditures, including salaries, benefits, and stock-based compensation for scientific and technical staff. It serves as a key indicator of the company's investment in human capital dedicated to advancing its proprietary genetic medicine pipeline and base editing technology. Monitoring this expense helps investors assess the company's commitment to innovation and the scalability of its research operations.